Role of EFNA1 in tumorigenesis and prospects for cancer therapy - 27/10/20
pages | 10 |
Iconographies | 5 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | EFNA1 is overexpressed in many cancers and may be used as a prognostic factor. |
• | EFNA1 may be induced by hypoxia in a HIF-dependent pathway and promotes angiogenesis in tumors. |
• | EFNA1 participates in the process of tumor cell proliferation, invasiveness and metastasis via its interaction with EphA2. |
• | EFNA1 is associated with the resistance of tumor cells to radiotherapy, chemotherapy, and photodynamic therapy. |
• | Several potential cancer therapy strategies based on EFNA1 have been reported. |
Abstract |
Cancer is one of the major threats to human health. It is of vital importance to reveal the mechanisms of tumorigenesis, identify effective biomarkers and develop novel treatments to improve patient outcome. EFNA1 (ephrinA1) is a member of the EFN family, and it has been studied extensively since its discovery in 1990. Increasing evidence indicates that EFNA1 plays a pivotal role in the pathogenesis of tumors. We provide a detailed overview of the expression and prognostic value of EFNA1 in different types of human malignancies. We briefly discuss the mechanisms of EFNA1 induction in hypoxic environments and its pro-angiogenic function in different cancer cells. We describe the effects of EFNA1 on tumor growth, invasiveness and metastasis. We summarize recent advances in EFNA1-associated cancer therapeutics with emphasis on the prospect of novel anti-tumor methods based on EFNA1.
Le texte complet de cet article est disponible en PDF.Abbreviations : RTK, SAM, GPI, TNF, C1GALT1, HUVEC, MAPK, SAPK, JNK, MMP, GC, CRC, DSS, SNP, GMAN, DFS, CSS, PFS, NSCLC, OS, GBM, Had, AFP, HCC, MVD, CS, ESCC, LSCC, HIF-1α, HIF-2α, HRE, EC, PEG, IPA, HUVEC, PI3K, PIP2, PIP3, S1P, eNOS, VEGF, CAF, EMT, GSC, TPC, MM, Mcl-1, ADAM12, MSC, MS, Hu-SCID, LNP, TMB, LEF, PDT
Keywords : EFNA1, Tumorigenesis, Angiogenesis, Therapeutics, Hypoxia
Plan
Vol 130
Article 110567- octobre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?